All In MedTech

Device Trial Radar · NCT07941531

T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2032

Study completion Dec 2034

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 17, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD7 negative T-cells expressing CD7-CARs (CD7-CAR T cells) in pediatric patients with recurrent/refractory CD7+ hematological malignancies after lymphodepleting chemotherapy. Secondary Objectives: To evaluate the antileukemic activity of CD7-CAR T cells. As a phase I study, efficacy is not the primary objective of this study, but remains an important outcome to evaluate. We will determine the anti-leukemic activity of the CD7-CAR T cells in the bone marrow and in the treatment of extramedullary disease.

Conditions

  • Lymphoma
  • AML
  • T-ALL
  • Hematologic Malignancy

Interventions

  • FludarabineDrug

    Day 4, 3, 2 at 40 mg/m2 dose. Intravenous.

  • CyclophosphamideDrug

    Day -2 at 90mg/m2 dose. Intravenous infusion.

  • CliniMACSDevice

    CD7-CAR T-cell infusion

  • MesnaDrug

    Given intravenously divided as 4 doses equal to 25% cyclophosphamide dose per dose of Mesna administered prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of CD7-CAR T cells (Arm A)Time frame: up to 4 weeks after CD7CAR T-cell infusion
  2. Maximum Tolerated Dose (MTD) of CD7-CAR T cells (Arm B)Time frame: up to 4 weeks after CD7CAR T-cell infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.